Dodge & Cox
BMRN icon

Dodge & Cox’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dodge & Cox’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$849M Buy
14,844,930
+283,171
+2% +$15.5M 0.44% 71
2026
Q1 		$823M Sell
14,561,759
-10,625
-0.1% -$620K 0.45% 70
2025
Q4 		$866M Sell
14,572,384
-114,417
-0.8% -$6.23M 0.47% 64
2025
Q3 		$795M Sell
14,686,801
-421,509
-3% -$24.1M 0.43% 70
2025
Q2 		$831M Buy
15,108,310
+153,070
+1% +$9.01M 0.47% 64
2025
Q1 		$1.06B Buy
14,955,240
+209,005
+1% +$14.1M 0.6% 57
2024
Q4 		$969M Buy
14,746,235
+847,917
+6% +$56.8M 0.56% 63
2024
Q3 		$977M Sell
13,898,318
-32,175
-0.2% -$2.69M 0.55% 62
2024
Q2 		$1.15B Sell
13,930,493
-62,450
-0.4% -$5.2M 0.69% 53
2024
Q1 		$1.22B Sell
13,992,943
-1,120
-0% -$100K 0.71% 51
2023
Q4 		$1.35B Sell
13,994,063
-159,440
-1% -$14.1M 0.86% 45
2023
Q3 		$1.25B Sell
14,153,503
-136,800
-1% -$12.2M 0.84% 50
2023
Q2 		$1.24B Sell
14,290,303
-39,010
-0.3% -$3.67M 0.83% 46
2023
Q1 		$1.39B Sell
14,329,313
-54,350
-0.4% -$5.63M 0.95% 41
2022
Q4 		$1.49B Sell
14,383,663
-390,300
-3% -$36.6M 1.02% 36
2022
Q3 		$1.25B Sell
14,773,963
-233,100
-2% -$20.8M 0.95% 42
2022
Q2 		$1.24B Sell
15,007,063
-27,936
-0.2% -$2.22M 0.86% 47
2022
Q1 		$1.16B Buy
15,034,999
+209,950
+1% +$17.6M 0.7% 51
2021
Q4 		$1.31B Buy
14,825,049
+6,467
+0% +$534K 0.81% 46
2021
Q3 		$1.15B Buy
14,818,582
+716,485
+5% +$56.5M 0.75% 50
2021
Q2 		$1.18B Buy
14,102,097
+2,247,789
+19% +$178M 0.77% 49
2021
Q1 		$895M Buy
11,854,308
+2,057,384
+21% +$168M 0.64% 52
2020
Q4 		$859M Buy
9,796,924
+2,076,701
+27% +$165M 0.68% 51
2020
Q3 		$587M Buy
7,720,223
+4,104,483
+114% +$415M 0.54% 57
2020
Q2 		$446M Sell
3,615,740
-326,768
-8% -$32.5M 0.41% 63
2020
Q1 		$333M Sell
3,942,508
-447,007
-10% -$38.5M 0.36% 61
2019
Q4 		$371M Buy
+4,389,515
New +$332M 0.28% 72

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox's BMRN Position: Q2 2026 in Review

Dodge & Cox increased its BioMarin Pharmaceuticals (BMRN) stake by 1.9% in Q2 2026, buying an estimated $15.5M and bringing the position to 14,844,930 shares worth $849M. The position accounts for 0.44% of the portfolio, ranked #71.

Dodge & Cox first reported a position in BMRN in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.49B in Q4 2022. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Dodge & Cox held 14,844,930 shares of BioMarin Pharmaceuticals worth $849M as of Q2 2026.
  • Dodge & Cox bought 283,171 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $15.5M.
  • BioMarin Pharmaceuticals made up 0.44% of Dodge & Cox's portfolio in Q2 2026, its #71 holding.
  • Dodge & Cox first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Dodge & Cox's BioMarin Pharmaceuticals position peaked at $1.49B in Q4 2022.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Dodge & Cox's 13F filing for Q2 2026, filed 13 Aug 2026.